CD49d双峰表达促进慢性淋巴细胞白血病疾病进展
该研究分析1630例慢性淋巴细胞白血病(CLL)样本,发现约20%(n=313)存在CD49d双峰表达(CD49d+与CD49d-亚群并存)。双峰表达者CD49d+亚群增殖更高且富集于骨髓及CXCR4dim/CD5bright表型;无论CD49d+亚群是否超过30%阈值,其临床行为均类似CD49d+ CLL(免疫化疗n=1522,依鲁替尼n=158)。提示CD49d驱动疾病进展,评估CD49d表达模式可提升其预后价值。
要点
- 约20%的CLL患者呈CD49d双峰表达,其CD49d+亚群比例随治疗后可升高。
- 双峰表达者CD49d+亚群增殖活跃,富集于骨髓和CXCR4dim/CD5bright表型。
- 双峰表达CLL的临床行为类似CD49d+ CLL,与CD49d+亚群是否超30%无关。
核心结论
- CD49d可驱动CLL疾病进展,评估CD49d表达模式(双峰与否)应纳入以提升该标志物的预后价值。
研究设计与样本
- 回顾性分析1630例CLL样本,其中CD49d双峰表达者313例(约20%);免疫化疗队列n=1522,依鲁替尼队列n=158。
主要发现
- CD49d双峰CLL在连续样本中CD49d表达变异性高于均一表达者,且治疗后CD49d+亚群随时间增加。
- 双峰CLL的CD49d+亚群增殖水平高于CD49d-细胞,在骨髓中占比高于外周血,并在CXCR4dim/CD5bright表型中富集。
- 无论CD49d+亚群是否超过30%阈值,双峰表达者的临床行为均类似CD49d+ CLL(免疫化疗n=1522,依鲁替尼n=158)。
关键数值与推荐
- CD49d阳性阈值沿用广泛验证的30%阳性CLL细胞。
- CD49d双峰表达定义为CD49d+亚群与CD49d-亚群并存。
临床怎么用
- 解读CLL的CD49d预后时,除30%阈值外还应关注是否存在双峰表达模式。
- 双峰表达者即使CD49d+亚群未超30%,也应视为具有类似CD49d+ CLL的临床行为。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL). The cutoff value for the extensively validated 30% of positive CLL cells is able to separate CLL patients into 2 subgroups with different prognoses, but it does not consider the pattern of CD49d expression. In the present study, we analyzed a cohort of 1630 CLL samples and identified the presence of ∼20% of CLL cases (n = 313) characterized by a bimodal expression of CD49d, that is, concomitant presence of a CD49d+ subpopulation and a CD49d- subpopulation. At variance with the highly stable CD49d expression observed in CLL patients with a homogeneous pattern of CD49d expression, CD49d bimodal CLL showed a higher level of variability in sequential samples, and an increase in the CD49d+ subpopulation over time after therapy. The CD49d+ subpopulation from CD49d bimodal CLL displayed higher levels of proliferation compared with the CD49d- cells; and was more highly represented in the bone marrow compared with peripheral blood (PB), and in PB CLL subsets expressing the CXCR4dim/CD5bright phenotype, known to be enriched in proliferative cells. From a clinical standpoint, CLL patients with CD49d bimodal expression, regardless of whether the CD49d+ subpopulation exceeded the 30% cutoff or not, experienced clinical behavior similar to CD49d+ CLL, both in chemoimmunotherapy (n = 1522) and in ibrutinib (n = 158) settings. Altogether, these results suggest that CD49d can drive disease progression in CLL, and that the pattern of CD49d expression should also be considered to improve the prognostic impact of this biomarker in CLL.
引用
- Tissino E, Pozzo F, Benedetti D, et al. CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood. 2020. PMID: 32006000. doi:10.1182/blood.2019003179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。